Real-World Evidence and the Evolving Treatment Landscape in Advanced Melanoma

In this OncLive Medical News Network discussion, two melanoma experts explore how emerging real-world evidence is reshaping the management of unresectable and metastatic melanoma. The conversation centers on tumor-infiltrating lymphocyte therapy, a one-time cellular treatment now available for patients whose disease has progressed on checkpoint inhibitors and other standard-of-care options. The faculty examine where this therapy fits within the broader treatment landscape, offering eligible patients a meaningful chance at durable, long-term remission. Drawing on recent multicenter and single-center retrospective analyses, they discuss how real-world outcomes are validating pivotal trial findings across a broader patient population, with no new safety signals identified. The discussion offers practical, experience-driven insight into patient selection, the importance of earlier referral, the treatment journey from tumor procurement through recovery, safety management, and individualized approaches to IL-2 dosing. Throughout, the experts emphasize thoughtful sequencing and timely referral to optimize patient outcomes.